Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. They presently have a $18.00 target price on the stock, down from their prior target price of $21.00. Wedbush's price target would indicate a potential upside of 282.17% from the company's previous close.

A number of other research firms also recently commented on YMAB. Bank of America downgraded shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. Truist Financial decreased their price objective on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a report on Wednesday, March 5th. HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Oppenheimer decreased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB traded down $0.04 during midday trading on Wednesday, reaching $4.71. The company had a trading volume of 253,129 shares, compared to its average volume of 310,963. The stock's fifty day moving average price is $4.37 and its 200-day moving average price is $6.38. The stock has a market capitalization of $213.29 million, a P/E ratio of -8.72 and a beta of 0.53. Y-mAbs Therapeutics has a one year low of $3.55 and a one year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. As a group, sell-side analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.50% of the company's stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of YMAB. Brooklyn Investment Group raised its stake in shares of Y-mAbs Therapeutics by 4,563.8% during the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after purchasing an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Y-mAbs Therapeutics during the first quarter valued at about $49,000. Corton Capital Inc. bought a new stake in Y-mAbs Therapeutics in the first quarter worth about $55,000. Finally, EntryPoint Capital LLC bought a new stake in Y-mAbs Therapeutics in the first quarter worth about $56,000. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.